Skip to main content

Table 1 Baseline characteristics

From: Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial

Items

TOCE

TOCE + HAIC

Provability

n = 9

n = 10

Age (years)

Median

81

72

0.22

Range

55–85

36–84

Gender

Female

2

5

0.09

Male

7

5

Performance status

0/1

8/1

10/0

0.47

Etiology

HBV infection

1

1

0.32

HCV infection

7

5

Alcohol

0

1

NASH

0

1

Autoimmune hepatitis

0

1

Primary Biliary Cirrhosis

0

1

Unknown Etiology

1

0

Cirrhosis (Yes/No)

 

9/0

10/0

1.00

Child-Pugh Grade

A/B/C

8/1/0

7/3/0

0.36

Size (mm)

Median

22

21.5

0.87

Range

10–32

10–85

Number

1

0

1

0.41

≤3

4

1

>3

5

8

TNM

I/II/III

0/3/6

0/5/5

0.55

BCLC

0/A/B/C/D

0/3/6/0/0

0/2/8/0/0

0.65

Previous Treatment

DDP-H

8

7

 

TACE

9

6

0.51

  1. TOCE, transarterial oily chemoembolization; TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy; NASH, non-alcoholic steatohepatitis; BCLC, Barcelona-Clinic Liver Cancer staging classification